Patents by Inventor Jonathan M. Solomon

Jonathan M. Solomon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION
    Publication number: 20200339704
    Abstract: The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a COF1/CRBN-binding polypeptide, COF2/CRBN-binding polypeptide, or COF3/CRBN-binding polypeptide and a heterologous polypeptide of interest.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 29, 2020
    Inventors: James E. Bradner, Andrei Golosov, Carleton Proctor Goold, Carla Patricia Pinto Guimaraes, Marc Horst Peter Hild, Gregory Motz, Nathan Thomas Ross, Jonathan M. Solomon, Rohan Eric John Beckwith, Seth Carbonneau
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20160113903
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 28, 2016
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • SirT INHIBITORS THAT BIND TO NAD
    Publication number: 20140163029
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: May 24, 2013
    Publication date: June 12, 2014
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew D. Napper, Peter DiStefano, Rory Curtis, Jeffrey Hixon, Thomas E. McDonagh, L. Julie Huber, Jonathan M. Solomon, Russel J. Thomas, Jean-francois Pons
  • SirT inhibitors that bind to NAD
    Patent number: 8486990
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: July 16, 2013
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • Cytochrome c acetylation
    Patent number: 7771961
    Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: August 10, 2010
    Assignee: Elixir Pharmaceuticals, Inc
    Inventors: L. Julie Huber, Jonathan M. Solomon
  • CYTOCHROME C ACETYLATION
    Publication number: 20100015043
    Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.
    Type: Application
    Filed: July 10, 2009
    Publication date: January 21, 2010
    Inventors: L. Julie Huber, Jonathan M. Solomon
  • SirT Inhibitors That Bind to NAD
    Publication number: 20090306168
    Abstract: Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.
    Type: Application
    Filed: April 14, 2009
    Publication date: December 10, 2009
    Applicant: ELIXIR PHARMACEUTICALS, INC.
    Inventors: Andrew Napper, Peter DiStefano, Rory A. Curtis, Jeffrey Hixon, Thomas McDonagh, L. Julie Huber, Jonathan M. Solomon, Russell J. Thomas, Jean-Francois Pons
  • Cytochrome c acetylation
    Patent number: 7575883
    Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: August 18, 2009
    Assignee: Elixir Pharmaceuticals, Inc.
    Inventors: L. Julie Huber, Jonathan M. Solomon